Venture NAV Tracker / Private company
Kura Oncology, Inc.
Headquarters—
Founded—
Last known round—
Reported valuation—
+1844.2% equity-mark dispersion. Hercules Capital, Inc. carries Kura Oncology, Inc. at $0.42/share; Hercules Capital, Inc. carries it at $8.13/share. Review dates and security types before treating those marks as directly comparable.
Cross-fund comparison
Equity & warrant marks
One latest disclosed mark per fund.
| Fund | Fair value | Security / basis | Implied price / share | Mark age vs round | Methodology / filing |
|---|---|---|---|---|---|
| HTGCHercules Capital, Inc. | $389KMar 31, 2026 · source ↗ | equityFair Value | $8.13Not comparable — different security type or share classMar 31, 2026 · source ↗ | —Mar 31, 2026 · source ↗ | 10-Q 2026-03-31 ↗ |
| HTGCHercules Capital, Inc. | $6KMar 31, 2026 · source ↗ | warrantFair Value | $0.42Not comparable — different security type or share classMar 31, 2026 · source ↗ | —Mar 31, 2026 · source ↗ | 10-Q 2026-03-31 ↗ |
Cross-fund comparison
Debt investments
One latest disclosed debt mark per fund.
| Fund | Security type / basis | Principal | Fair value | FV / principal | Rate | Maturity | Mark age vs round | Non-accrual |
|---|---|---|---|---|---|---|---|---|
| HTGCHercules Capital, Inc. | senior secured loanFair Value — Senior Secured | $5.5MMar 31, 2026 · source ↗ | $5.8MMar 31, 2026 · source ↗ | 105.5%Mar 31, 2026 · source ↗ | Prime + 2.40 %, Floor rate 8.65 %, 6.05 % Exit FeeMar 31, 2026 · source ↗ | Nov 1, 2027Mar 31, 2026 · source ↗ | —Mar 31, 2026 · source ↗ | NoMar 31, 2026 · source ↗ |
Historical marks
Reported fair value by fund
Each bar is a disclosed position-quarter.